Supernus Pharmaceuticals (SUPN) Research & Development (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Research & Development data on file, last reported at $27.8 million in Q4 2025.

• Research & Development for Q4 2025 came in at $27.8 million, down 2.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $106.2 million (down 2.35% YoY), and the FY2025 annual result was $106.2 million, down 2.35% from the prior year.
• Research & Development retreated to $27.8 million in Q4 2025 per SUPN's latest filing, from $29.4 million in the prior quarter.
• Over five years, Research & Development peaked at $29.4 million in Q3 2025 and troughed at $15.0 million in Q1 2021.
• A 5-year average of $22.6 million and a median of $22.4 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2023: Research & Development slumped 30.53% in 2021, then soared 48.79% in 2023.
• A 5-year view of Research & Development shows it stood at $21.1 million in 2021, then dropped by 15.68% to $17.8 million in 2022, then jumped by 31.35% to $23.3 million in 2023, then gained by 22.7% to $28.6 million in 2024, then decreased by 2.86% to $27.8 million in 2025.
• Business Quant data shows SUPN's Research & Development at $27.8 million in Q4 2025, $29.4 million in Q3 2025, and $22.1 million in Q2 2025.